Navigation Links
Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
Date:8/27/2010

EAST HANOVER, N.J., Aug. 27 /PRNewswire/ -- The US Food and Drug Administration (FDA) approved Tekamlo™ (aliskiren and amlodipine) tablets, a single-pill for the treatment of high blood pressure combining the only approved direct renin inhibitor, Tekturna® (aliskiren), with the widely used calcium channel blocker amlodipine. Tekamlo is approved as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals, and as replacement therapy for patients whose blood pressure is not adequately controlled with either aliskiren or amlodipine alone.

"We welcome the FDA's decision to approve Tekamlo, as the treatment of high blood pressure remains a challenge for many patients, requiring multiple medications to control their condition," said David Epstein, Division Head of Novartis Pharmaceuticals. "This approval reinforces Novartis' commitment to cardiovascular research and to developing innovative and effective treatments for patients who have not reached their blood pressure goal."

The FDA approval of Tekamlo was based on clinical trial data involving more than 5,000 patients with mild-to-moderate high blood pressure. An eight-week, randomized, double-blind, placebo-controlled, multi-factorial study showed that the combination of Tekturna and amlodipine resulted in decreases in systolic/diastolic blood pressure at trough of 14-17/9-11 mmHg, compared to 4-9/3-4 mmHg for Tekturna alone, and 9-14/6-8 mmHg for amlodipine alone.

In two additional double-blind, active-controlled studies of similar design evaluating patients with moderate-to-severe high blood pressure (SBP 160 - 200 mmHg), Tekamlo demonstrated significantly greater reductions in systolic and diastolic blood pressures when compared to amlodipine alone. In one study of 443 Black patients, the systolic/diastolic treatment difference between Tekamlo and amlodipine was 5.2/3.8 mmHg at the primary endpoint of eight week
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015  Nevro Corp. ... company that is providing innovative evidence-based solutions for ... publication of the SENZA-RCT results in the Online ... of the American Society of Anesthesiologists. ... study that was the first to directly compare ...
(Date:7/28/2015)... Research and Markets ... the "Craniomaxillofacial Implants Market - Global Industry ... - 2022" report to their offering. ... studies the current and future prospects of the ... in the global market due to increasing facial ...
(Date:7/28/2015)... OKLAHOMA CITY , July 28, 2015 /PRNewswire/ ... PDRX) today announced that it has partnered with ... their Infrastructure as a Service (IaaS) product. ... to medical practices across the United States.  Using ... improve disaster recovery and business continuity, ensure regulatory ...
Breaking Medicine Technology:Nevro Announces Publication of SENZA-RCT Results in Anesthesiology 2Global Craniomaxillofacial Implants (Plate and Screw Fixator Systems, Bone Graft Substitutes, Distraction Systems, and TMJ Replacement Devices) Market Analysis 2014-2022 2PD-Rx Partners With Dobson Technologies 2
... MONTVALE, N.J., Dec. 15 Synvista Therapeutics, Inc. ... has dosed the first patient in a 30-patient Phase ... in patients with psoriasis. The trial is planned to ... to assess the efficacy of topical SYI-2074, applied twice ...
... the,largest studies of its kind, a multinational team led ... report the discovery of common variations,at seven new sites ... study,analyzed more than 300,000 single-letter variations (SNPs) across the ... and the United,States, and confirmed the findings in data ...
Cached Medicine Technology:Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis 2Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis 3Major deCODE-led Study Underscores Role of the Brain in Obesity 2Major deCODE-led Study Underscores Role of the Brain in Obesity 3Major deCODE-led Study Underscores Role of the Brain in Obesity 4Major deCODE-led Study Underscores Role of the Brain in Obesity 5
(Date:7/28/2015)... ... 2015 , ... The Denver Foundation and Blair-Caldwell African American ... a photographic and narrative exploration of African American giving, which runs August 1-31 ... Denver is one of only ten cities to host “The Soul of Philanthropy ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... 1 in 68 children currently affected with the disorder. For these families, identifying ... road to recovery is extremely daunting. That’s where Talk About Curing Autism (TACA), ...
(Date:7/28/2015)... ... July 16, 2015 (PRWEB) July 28, 2015 , ... ... providing Health insurance quotes to its clients, recently announced the launch of Commercial, ... best suits their specific needs. , Liability automobile insurance policies are one ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Dr. Aziz Ahmad ... The talk took place from noon to 1 p.m. Tuesday, June 23, at the ... Fla. , Dr. Ahmad is board-certified in colorectal surgery and has more than ...
(Date:7/28/2015)... La Mirada, CA (PRWEB) , ... July 28, 2015 , ... ... XC, a collagen-filling injectable that returns skin to a smooth state, and reduces the ... XC is the “first and only FDA-approved injectable gel to instantly add volume to ...
Breaking Medicine News(10 mins):Health News:"The Soul of Philanthropy Reframed and Exhibited” Comes to Denver 2Health News:National TACA Autism Conference Offers Hope and Help to Families Affected by Autism 2Health News:Nations Insurance Solutions Announces Auto, Motorcycle, and Commercial Business Insurance Quotes. 2Health News:Dr. Aziz Ahmad Delivers Talk at Gulf Coast Medical Center 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 3
... 7 Diabetes America, the premier network,of diabetes care ... that five of its physicians have been recognized by ... to their patients. Dr. Wendy Hawkins M.D., Dr. Damon,Weddington ... and Dr. Eddie,Tejeda M.D. were all honored in Houston ...
... Face Recognition Engines, VILNIUS, Lithuania, Nov. ... identification technologies, today,announced the availability of the ... MegaMatcher face identification engines. Like the,Smartcard Finger-Match ... verifies biometric facial information on a smartcard, ...
... Nov. 7 /PRNewswire-FirstCall/ - Cipher Pharmaceuticals,Inc. (TSX: DND) today announced ... ended September 30, 2007. Q3 2007 Summary --------------- ... agreement with ProEthic Pharmaceuticals under ... to market, sell and distribute CIP-FENOFIBRATE (approved and ...
... factor for prostate, breast and colon cancer, but recent ... fat cells also plays an important role in cancer. ... for the first time, a genome-wide analysis of how ... on various genes related to obesity. , ...
... to Significantly Grow Lutein Usage Globally, LAS ... Kemin,Health, L.C. (Kemin), creator of FloraGLO(R) lutein the ... the premium supplier of,vitamins, carotenoids, and nutraceuticals, announced ... usage and the eye health,supplement category worldwide. ...
... affect both domestic and imported items, agency says , , ... U.S. outbreaks of illness linked to domestic and imported ... ask Congress to give it the authority to force ... officials announced Tuesday. , Currently, the agency can only ...
Cached Medicine News:Health News:Diabetes America Physicians Achieve Industry Recognition for Quality Patient Care 2Health News:Neurotechnologija Releases Smartcard Face-Match Add-on for the Implementation of Biometric Face-on-Smartcard Verification Systems 2Health News:Neurotechnologija Releases Smartcard Face-Match Add-on for the Implementation of Biometric Face-on-Smartcard Verification Systems 3Health News:Cipher reports third quarter fiscal 2007 results 2Health News:Cipher reports third quarter fiscal 2007 results 3Health News:Cipher reports third quarter fiscal 2007 results 4Health News:Cipher reports third quarter fiscal 2007 results 5Health News:Cipher reports third quarter fiscal 2007 results 6Health News:Cipher reports third quarter fiscal 2007 results 7Health News:Cipher reports third quarter fiscal 2007 results 8Health News:Cipher reports third quarter fiscal 2007 results 9Health News:Cipher reports third quarter fiscal 2007 results 10Health News:Cipher reports third quarter fiscal 2007 results 11Health News:Cipher reports third quarter fiscal 2007 results 12Health News:Cipher reports third quarter fiscal 2007 results 13Health News:Cipher reports third quarter fiscal 2007 results 14Health News:Cipher reports third quarter fiscal 2007 results 15Health News:Cipher reports third quarter fiscal 2007 results 16Health News:Cipher reports third quarter fiscal 2007 results 17Health News:Cipher reports third quarter fiscal 2007 results 18Health News:Cipher reports third quarter fiscal 2007 results 19Health News:Cipher reports third quarter fiscal 2007 results 20Health News:Researchers chart the genetic mechanisms behind the genesis of fat cells 2Health News:Kemin and DSM Forge Long-Term Strategic Alliance 2Health News:Kemin and DSM Forge Long-Term Strategic Alliance 3Health News:FDA Seeks Food Recall Authority 2Health News:FDA Seeks Food Recall Authority 3
Used to remove wrinkles from sections and for reorientating embedded tissue....
Liquichek Blood Gas Plus CO-Oximeter Control (Radiometer) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximeter (Radiometer) ...
Liquichek Blood Gas Plus E Control is an aqueous product used to monitor the measurement of pH, pCO2, pO2 and electrolytes. Available in four levels....
Bio-Rad's Liquichek™ D-dimer Control provides the laboratory with a liquid, trilevel, human plasma based control for the monitoring of D-dimer testing on most automated coagulation, chemistry a...
Medicine Products: